The long-term goals of this PPG are to understand the pathogenesis of myeloid leukemias and myeloproliferative disorders (MPDs) and use this information to develop novel and effective therapies. It is proposed that the ideal targets for therapy are the protein products of the oncogenes that cause acute or chronic myeloid diseases, and this proposal will continue to focus on tyrosine kinases. In the last cycle of this grant, this project focused on understanding the role that mutations in FLT3 play in causing AML and on testing the concept that mutant FLT3 was a valid target for drug therapy. The hypothesis was that inhibition of FLT3 tyrosine kinase activity would be cytotoxic for AML cells and would therefore potentially be of significant therapeutic benefit. We were instrumental in bringing two FLT3 inhibitors to clinical trials, and early phase studies were sufficiently encouraging that at least one of these agents will undergo phase III testing in induction therapy of patients with AML and mutated FLT3 in a cooperative group setting (see project 5). Here, we propose to continue our efforts to understand how to optimally target mutant FLT3, and in addition, propose to initiate specific, focused projects on two other tyrosine kinases mutated in myeloid leukemias, KIT and JAK2. The major focus of the proposal remains on FLT3, The proposed studies are aimed at testing the hypothesis that """"""""combination targeted therapy"""""""" for AML has more therapeutic value than use of a kinase inhibitor alone. For example, we predict that targeting both a mutant oncogene, such as FLT3-ITD, and a critical downstream pathway mediating enhanced viability of leukemic cells, such as PI3K, is highly likely to be synergistic. We will also develop higher affinity inhibitors and carefully study resistance mechanisms. If successful, we hope to have a much better understanding of how to design the next generation of FLT3 kinase inhibitor trials in AML. In two other, smaller, specific aims, we propose some focused studies on two other tyrosine kinases that are mutated in either AML (KIT) or Polycythemia Vera (JAK2). These studies will explore therapeutic targeting of these kinases in preclinical models, with the goal of developing clinical trials that can later be conducted in Project 5.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-13
Application #
8063507
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
13
Fiscal Year
2010
Total Cost
$315,567
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bolin, Sara; Borgenvik, Anna; Persson, Camilla U et al. (2018) Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene 37:2850-2862
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117

Showing the most recent 10 out of 376 publications